
Manzi discussed findings from the phase 3 TULIP-SC trial of subcutaneous anifrolumab for systemic lupus erythematosus.

Chair of the Allegheny Health Network (AHN) Medicine Institute and director of the Lupus Center of Excellence at the AHN Autoimmunity Institute

Manzi discussed findings from the phase 3 TULIP-SC trial of subcutaneous anifrolumab for systemic lupus erythematosus.